Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). RB’s SUBOXONE® and SUBUTEX® tablet manufacturing agreement terminates early on January 15, 2027.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- RB’s SUBOXONE® and SUBUTEX® tablet manufacturing agreement terminates early on January 15, 2027
- New supplier identified, with enforceable obligations beginning after manufacturing-process validation
- RB to produce additional units before termination, supporting transition supply continuity
- Indivior assumes fixed or capped transition costs, including volume shortfalls, asset disposal, depreciation, redundancy, and incentives
- Costs not expected to be material to Indivior Pharmaceuticals, Inc.
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.